Jardiance also met the trials secondary endpoint, showing a 14% reduction in the risk of first and recurrent hospitalization compared to placebo, a result that was deemed significant
Image Credit: Liya Graphics / Shutterstock In a recent study published in The Lancet , researchers examined the associations between baseline adiposity measures, treatment-induced adiposity changes, and the risk of major adverse cardiovascular events (MACE) in the semaglutide effects on cardiovascular outcomes in people with overweight and obesity (SELECT) trial
Available to be shipped to your home or for injection administration in one of our clinics
Kornelius E, et al
Dulaglutide is administrated in combination with other drugs, together with exercise and diet, to improve glycemic control
No, it is not FDA-approved, and much of the evidence is preclinical